Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino acid peptide that has been explored in laboratory research models for its potential involvement in immune-related biological pathways.

In mammalian research settings, it has been observed to:

• Interact with receptors on immune cells such as T-cells and dendritic cells

• Participate in intracellular signaling pathways associated with cell communication

• Influence signaling molecules (e.g., interleukin-2 and interferon-gamma) in experimental environments

• Be studied for its potential to affect natural killer (NK) cell activity

• Contribute to the understanding of immune cell maturation and cytokine behavior in controlled settings

Thymosin Alpha-1 has been studied in preclinical laboratory settings, primarily using mammalian models, to explore its role in various biological systems:

• Cellular Signaling-Investigated in relation to immune cell behavior and receptor interactions under controlled experimental conditions

• Adjuvant Research-Evaluated in studies examining how it may modulate immune responses in conjunction with other research compounds

• Immunological Studies-Explored in the context of primary and secondary immune system activity in non-human models

• Tissue Response-Studied for its potential influence on cellular migration and signaling pathways related to tissue integrity

 In published preclinical and laboratory studies, Thymosin Alpha-1 has been evaluated for its role in immune system function. These studies have been conducted primarily in mammalian models or in vitro and are not intended to suggest safety or efficacy in humans. Comprehensive human safety data is not available, and this compound is not approved for human or veterinary use.

Thymosin Alpha-1 is a synthetic 28-amino acid peptide modeled after a sequence found in the thymus gland. It has been studied in preclinical and laboratory environments for its role in cellular signaling and immune system function. In mammalian research models, it has been observed to influence biological processes such as T-cell behavior and intercellular signaling. These studies contribute to ongoing scientific exploration in the fields of immunological research and basic cellular biology. While research continues into its biological activity, Thymosin Alpha-1 is not approved for therapeutic use. Its use is limited to laboratory settings.

1. Garaci E, Pica F, Rasi G, Favalli C. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000 Dec;22(12):1067-76. doi: 10.1016/s0192-0561(00)00075-8. PMID: 11137613.

2. King, Cynthia. (2013). Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications. Clinical & Experimental Pharmacology. 03. 10.4172/2161-1459.1000133. 

3. Serafino A, Pierimarchi P, Pica F, Andreola F, Gaziano R, Moroni N, Zonfrillo M, Sinibaldi-Vallebona P, Garaci E. Thymosin α1 as a stimulatory agent of innate cell-mediated immune response. Ann N Y Acad Sci. 2012 Oct;1270:13-20. doi: 10.1111/j.1749-6632.2012.06707.x. PMID: 23050812.

4. Tao N, Xu X, Ying Y, Hu S, Sun Q, Lv G, Gao J. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023; 28(8):3539. https://doi.org/10.3390/molecules28083539

5. Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P, Sinibaldi-Vallebona P. Thymosin α1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012 Oct;1269:26-33. doi: 10.1111/j.1749-6632.2012.06697.x. PMID: 23045967.

6. Costantini C, Bellet MM, Pariano M, Renga G, Stincardini C, Goldstein AL, Garaci E, Romani L. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019 Sep 6;9:873. doi: 10.3389/fonc.2019.00873. PMID: 31555601; PMCID: PMC6742685.